Progenitor cell

Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration

Retrieved on:

Wednesday, May 3, 2023

University, The Angiogenesis Foundation, Microcirculation, Progenitor cell, Scar, AVE, Research, Inflammation, Dermatology, Regeneration, AV, Mouse, Architecture, CZO, Wound healing, Pharmaceutical industry, Medical imaging

EDMONTON, Alberta, May 03, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today positive results from a research collaboration with the Angiogenesis Foundation (“Foundation”) conducted with colleagues at the University of Arizona. The aim of this study was to assess the in vivo bioactivity of Ceapro products on angiogenesis, wound healing, tissue repair, and regeneration.

Key Points:

The aim of this study was to assess the in vivo bioactivity of Ceapro products on angiogenesis, wound healing, tissue repair, and regeneration.
Tissue analysis revealed that:
1% AVE treatment resulted in decreased tissue inflammation and the healed tissue had less scarring and an architecture more resembling normal tissue compared to that of scar tissue after control treatment.
The researchers concluded that oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation.
Gilles Gagnon, President and CEO of Ceapro, stated, “We are excited with these positive results showing efficacy of our two value drivers beta glucan and avenanthramides.

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

Retrieved on:

Friday, July 23, 2021

AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (LyGenesis), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement.

Key Points:

AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (LyGenesis), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement.
AgeX remains committed to creating shareholder value through third-party collaborations and licensing agreements for its core technologies UniverCyte and PureStem, and its cell therapy programs, including AGEX-VASC1 and AGEX-BAT1.
AgeX Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging.
AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences

Retrieved on:

Tuesday, May 25, 2021

A replay of the presentations will be posted on the Frequency website following the event.

Key Points:

A replay of the presentations will be posted on the Frequency website following the event.
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.
The Companys progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.
The Companys lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function.

Brian C. Handerhan, MBA, takes on the newly created role of Vice President, Operations for Cell X Technologies, Inc.

Retrieved on:

Monday, May 3, 2021

Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Developmental biology, Cloning, Progenitor cell

b'CLEVELAND, May 3, 2021 /PRNewswire/ -- Cell X Technologies\' CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA,who will take on the newly created position of Vice President, Operations.

Key Points:

b'CLEVELAND, May 3, 2021 /PRNewswire/ -- Cell X Technologies\' CEO Peter Johnson MD, today announced an important new hire in Brian C. Handerhan, MBA,who will take on the newly created position of Vice President, Operations.
"\nFounded in 2017, Cell X Technologies, Inc. develops and provides equipment, software, and process management tools to support stem cell research and bio-fabrication.The company\'s Cell X Platform is the only end-to-end fully robotic culture automation and analysis system whose applications span the entire development pipeline for cell therapies.
Designed to remove time-consuming and costly effects of technician and process variability in cell product development, Cell X leverages advanced image analytics and precision automation to improve decision making, productivity and documentation.
Cell X Technologies is committed to contributing to the ongoing transformation of stem and other progenitor cell biology into safe, effective, and affordable diagnostics and therapeutic procedures that improve all of our lives.

Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021

Retrieved on:

Monday, April 26, 2021

Additional videos are available on the Media page of the Lineage website.\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Key Points:

Additional videos are available on the Media page of the Lineage website.\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
Lineage\xe2\x80\x99s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.
With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.
For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005027/en/\n'

Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration

Retrieved on:

Wednesday, April 7, 2021

The paper has been published by the prestigious Journal of Tissue Engineering and Regenerative Medicine.

Key Points:

The paper has been published by the prestigious Journal of Tissue Engineering and Regenerative Medicine.
The focus of this journal is therapeutic approaches which combine stem/progenitor cells with bioactive agents to restore, maintain, or improve tissue or organ function.
Vision loss due to degeneration of the retina, most commonly the macula, commonly appears with aging, comorbid cardiovascular conditions, genetics, or other exposures.
A panel member of the California Institute of Regenerative Medicine & Canadian Institutes of Health Research.

Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on:

Tuesday, January 5, 2021

Health, Stem cells, Clinical trials, General Health, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Progenitor cell

The presentation will be followed by a question and answer session to be held at 8:00 a.m.

Key Points:

The presentation will be followed by a question and answer session to be held at 8:00 a.m.
A live webcast of both the presentation and the breakout session can be accessed on the investors section of Frequencys website, investors.frequencytx.com .
A replay of the presentation will be posted on the Frequency website following the event.
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.

Sana Biotechnology Announces Acquisition of Oscine

Retrieved on:

Friday, October 30, 2020

Branches of biology, Biology, Life sciences, Glial cells, Stem cells, Cloning, Developmental biology, Glia, Biotechnology, Progenitor cell, Draft:Steven Goldman

SEATTLE, Oct. 30, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition ofOscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS).

Key Points:

SEATTLE, Oct. 30, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition ofOscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS).
"We are excited about the potential of the glial progenitor cell program Oscine has been developing to help patients with a number of different diseases of the brain.
Steve Goldman, M.D., Ph.D.,was Oscine's scientific founder and joins Sana as the Head of CNS Therapy.Dr.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients.

Scientists Engineer New Cancer Immunotherapy to Train Immune System in Cancer Fight

Retrieved on:

Thursday, October 29, 2020

Branches of biology, Medical specialties, Clinical medicine, Immunology, Oncology, Cell biology, Stem cells, Immune system, Immunotherapy, Metástasis, Progenitor cell, Cancer immunotherapy

This nanobiologic immunotherapy targets the bone marrow, where part of the immune system is formed, and activates a process called trained immunity.

Key Points:

This nanobiologic immunotherapy targets the bone marrow, where part of the immune system is formed, and activates a process called trained immunity.
This process reprograms bone marrow progenitor cells to produce "trained" innate immune cells that halt the growth of cancer, which is normally able to protect itself from the immune system with the help of other types of cells, called immunosuppressive cells.
This work for the first time demonstrates that trained immunity can be successfully and safely induced for the treatment of cancer.
Immunotherapies that are already part of standard cancer care, such as the drug that eliminated former President Jimmy Carter's metastatic melanoma, are also able to unmask cancer to the immune system, but they have limitations.

Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings

Retrieved on:

Tuesday, September 8, 2020

Biotechnology, Health, Stem cells, Pharmaceutical, Clinical trials, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Cloning, Developmental biology, Progenitor cell, Cantor Fitzgerald

ET

Key Points:

ET
Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit, September 22, 2020, 10:00 a.m.
ET
The Cantor Fitzgerald and Oppenheimer investor presentations will be available via webcast and may be viewed on the Investors & Media section of the Frequency website.
A replay of the presentations will be posted on the Frequency website and made available for at least 30 days following each event.
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.